依达拉奉联合疏血通注射液治疗老年急性脑梗死的临床疗效  

Clinical Efficacy of Edaravone Shuxuetong Injection in Treatment of Elderly Patients with Acute Cerebral Infarction

作　　者：辛佳[1] 赵喜庆[1] 张利[1] 孙明阳 石文建[1] XIN Jia;ZHAO Xiqing;ZHANG Li;SUN Mingyang;SHI Wenjian(Department of Neurosurgery,Tangshan People's Hospital,Tangshan 063000,China)

机构地区：[1]唐山市人民医院神经外科

出　　处：《医学综述》2019年第24期5021-5025,5048+5045-5047+5049-5066,共5页Medical Recapitulate

摘　　要：目的探讨依达拉奉联合疏血通注射液治疗老年急性脑梗死的临床疗效。方法选取2016年3月至2018年10月唐山市人民医院神经外科收治的91例老年急性脑梗死患者为研究对象,根据治疗方案不同分为两组,对照组(n=45)采用依达拉奉治疗,观察组(n=46)采用依达拉奉联合疏血通注射液治疗,两组给药方式均为每日2次,14 d为1个疗程,连续用药2个疗程。采用美国国立卫生研究院卒中量表(NIHSS)、中国脑卒中临床神经功能缺损程度评分量表(CSS)评价患者神经功能,分析两组患者的临床疗效及治疗前后基质金属蛋白酶-9(MMP-9)、血管内皮生长因子(VEGF)水平;采用改良Rankin量表评估患者的预后。结果观察组治疗总有效率明显高于对照组[95.7%(44/46)比77.8%(35/45)](P<0.05)。治疗前,两组NIHSS评分、CSS评分和血清MMP-9及VEGF水平比较差异无统计学意义(P>0.05);治疗后,观察组NIHSS评分、CSS评分明显低于对照组[(12.3±1.9)分比(16.8±2.5)分,(13.1±1.8)分比(17.6±2.2)分](P<0.05),MMP-9低于对照组[(181.2±55.3)μg/L比(215.5±57.8)μg/L],VEGF水平高于对照组[(260.5±52.6)ng/L比(223.8±43.3)ng/L](P<0.05),两组各指标组间、时点间、组间和时点间交互作用比较差异有统计学意义(P<0.05)。观察组预后良好率明显高于对照组[91.3%(42/46)比71.1%(32/45)](P<0.05)。结论依达拉奉联合疏血通注射液治疗老年急性脑梗死的临床效果显著,患者预后良好。Objective To explore the clinical effect of edaravone combined with Shuxuetong injection in the treatment of senile acute cerebral infarction.Methods A total of 91 elderly patients with acute cerebral infarction admitted to Department of Neurosurgery of Tangshan People's Hospital from Mar.2016 to Oct.2018 were included and divided into two groups according to different treatment plans.The control group(n=45)was treated with edaravone,and the observation group(n=46)was treated with edaravone combined with Shuxuetong injection.Both groups were treated twice a day,two courses of continuous medication with 14 days as one treatment course.The National Institutes of Health Stroke scale(NIHSS)and Chinese stroke clinical neurological deficit scale(CSS)were used to evaluate the neurological function of the patients.The total effective rate,matrix metalloproteinase-9(MMP-9)and vascular endothelial growth factor(VEGF)levels before and after treatment were analyzed.The prognosis of the patients was evaluated by the modified Rankin scale.Results The total effective rate of the observation group was significantly higher than that of the control group[95.7%(44/46)vs 77.8%(35/45)](P<0.05).Before treatment,there was no significant difference in NIHSS,CSS,MMP-9 and VEGF between the two groups (P>0.05).After treatment,the NIHSS score and CSS score of the observation group were significantly lower than those of the control group[(12.3±1.9)point vs(16.8±2.5)point,(13.1±1.8)point vs(17.6±2.2)point],MMP-9 was lower than that of the control group[(181.2±55.3)μg/L vs(215.5±57.8)μg/L],and VEGF level was higher than that of the control group[(260.5±52.6)ng/L vs(223.8±43.3)ng/L](P<0.05),there were statistically significant differences in different indexes between groups,time points and interactions of group and time point(P<0.05).The good prognosis rate of the observation group was significantly higher than that of the control group[91.3%(42/46)vs 71.1%(32/45)](P<0.05).Conclusion Edaravone combined with Shuxuetong injection has a

关 键 词：脑梗死 溶栓 疏血通注射液 依达拉奉 

分 类 号：R743.33[医药卫生—神经病学与精神病学]